Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 0.3 Mg/Eye Pegaptanib Sodium (Macugen) Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration (AMD) Lesions

NCT00324116 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00324116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00324116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 0.3 Mg/Eye Pegaptanib Sodium (Macugen) Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration (AMD) Lesions
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2006
Completion date
August 31, 2008
Enrollment
81 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration